Genprex Announces Collaboration with Roche to Validate TROP2 Biomarker for NSCLC

What Happened
Genprex, Inc. (filed Aug 3, 2026; Item 8.01) announced a collaboration with Roche Diagnostics to validate biomarkers—centered on TROP2—for selecting patients in non-small cell lung cancer (NSCLC) clinical trials. The company said its preclinical and clinical data link high TROP2 H-scores and low PTEN H-scores with patient response and longer progression-free survival (PFS). Roche Diagnostics, which received FDA Breakthrough Device Designation for the first AI-driven companion diagnostic using a TROP2 score, will perform assay validation using the same TROP2 antibody Genprex plans to use. Genprex expects to complete these validation studies by approximately the end of 2026 and to integrate results into its NSCLC clinical program thereafter, subject to validation outcomes.

Key Details

• Filing date: August 3, 2026 (Current Report on Form 8-K, Item 8.01).
• Biomarker findings: Genprex reported that TROP2 H-score >100 and PTEN H-score <100 correlated with longer PFS in its studies; intensity of TROP2 expression may also correlate with PFS.
• Roche involvement: Roche Diagnostics will perform assay validation and has FDA Breakthrough Device Designation for an AI-driven TROP2-based companion diagnostic. Genprex will use the same validated TROP2 antibody.
• Timeline: Genprex anticipates assay validation to be completed by approximately end of 2026, with subsequent integration into its NSCLC clinical program dependent on results.

Why It Matters
This collaboration targets more precise patient selection for NSCLC trials by validating a TROP2-based assay, which—if successful—could shorten identification and recruitment timelines and improve trial efficiency. For investors, the announcement ties Genprex’s clinical strategy to an FDA-recognized diagnostic effort (Roche’s Breakthrough Device Designation), but planned progress and timelines are forward-looking and conditional on validation results and other risks disclosed in Genprex’s filings.